Gilead Sciences (NASDAQ:GILD) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
A number of other research analysts have also issued reports on the company. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price for the company in a report on Friday, October 13th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. BMO Capital Markets decreased their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Mizuho lifted their target price on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $85.03.
Gilead Sciences (NASDAQ GILD) traded down $0.04 on Tuesday, hitting $79.02. The stock had a trading volume of 6,342,448 shares, compared to its average volume of 8,150,000. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The stock has a market capitalization of $103,190.00, a price-to-earnings ratio of 8.99, a P/E/G ratio of -1.68 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the business posted $2.75 earnings per share. The company’s quarterly revenue was down 13.2% on a year-over-year basis. research analysts expect that Gilead Sciences will post 8.53 earnings per share for the current year.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the sale, the insider now owns 3,070,099 shares in the company, valued at $230,656,537.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 461,666 shares of company stock worth $34,072,567. 1.30% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Keel Point LLC increased its position in shares of Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 12 shares in the last quarter. Paradigm Financial Advisors LLC increased its position in shares of Gilead Sciences by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 26 shares in the last quarter. West Oak Capital LLC grew its holdings in shares of Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the last quarter. First Heartland Consultants Inc. grew its holdings in shares of Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC grew its holdings in shares of Gilead Sciences by 0.4% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 41 shares during the last quarter. Institutional investors and hedge funds own 75.94% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/01/13/gilead-sciences-gild-stock-rating-lowered-by-bidaskclub.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.